Immuno-oncology
Annexin starts 2024 strong
Annexin Pharmaceuticals had a successful 2023 and the new year looks set to begin with continued success. Signals of impact have...
BioInvent reaches research milestone in collaboration with Exelixis
BioInvent has reached a research milestone in its collaboration...
Intervju
Elicera updates in conjunction with Cancer Immunotherapy Month
June is celebrated globally as Cancer Immunotherapy Month in...
Intervju
Well-funded Elicera prepared for clinic and business development
Cell and gene therapy company Elicera Therapeutics has made important...
Elicera on the potential of CAR T cells outside of blood cancer
CAR T-cell therapy is an emerging form of immunotherapy...
Intervju
Advancement in Eliceras 2022 opens up for intensive clinical year
In 2022, Elicera Therapeutics advanced – the only...
Elicera about the positive clinical effect in the cancer study
Elicera Therapeutics recently participated in the Oncolytic Virotherapy Summit...
Intervju
Bill Gates sees great potential in personalized cancer treatment
The prestigious journal MIT Technology Review has eighteen years...
Immunicum: Presentation and CEO interview from BioStock Live
BioStock Live
Immunicum's research director presented at cancer seminar with Nobel glory
James allison
PHI enters into immuno-oncology collaboration with major player
This morning, Phase Holographic Imaging announced that it...
CEO Immunicum: »There is great interest among international investors«
Immunicum's recent progress and exciting upcoming...